Search clinical trials for: Molecular risk factors

Total 122783 results

The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
University of Zurich
Swiss HIV Cohort Study

Recruiting

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

HIV Infections

Switzerland
Fudan University

Not yet recruiting

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer (QUEEN-Dream)

Neoadjuvant Therapy | Early Breast Cancer | TNBC, Triple Negative Breast Cancer

China
Fudan University

Not yet recruiting

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer (QUEEN-Neo)

Neoadjuvant Therapy | Early Breast Cancer | HR+HER2- Breast Cancer
Children's Oncology Group

Not yet recruiting

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Stage I Kidney Wilms Tumor | Stage II Kidney Wilms Tumor | Stage III Kidney Wilms Tumor | Stage IV Kidney Wilms Tumor
University of Salerno

Not yet recruiting

Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients (BESAFE)

Cardiovascular Diseases | Dyslipidemias | Lipid Metabolism Disorders | Statin Adverse Reaction
Fundacao Champalimaud

Not yet recruiting

Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab (KEYPARTNER)

Triple Negative Breast Cancer | Early Breast Cancer

Portugal
Mayo Clinic

Recruiting

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer

Prostate Adenocarcinoma | Oligometastatic Prostate Carcinoma

United States
Celgene

Not yet recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Large B-cell Lymphoma

United States, Canada, Argentina, Australia, Austria, Brazil, Bulgaria, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Japan, Korea, Republic of, Malaysia, Mexico, New Zealand, Norway, Poland, Portug... and more
St. Jude Children's Research Hospital

Not yet recruiting

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Mixed Phenotype Acute Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
Aristotle University Of Thessaloniki

Recruiting

Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels

Cardiovascular Prevention | Tissue Oxygenation | Empagliflozin | SGLT2-Inhibitors | Hematocrit Change

Greece
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Radiomics and Radiogenomics Models to Predict Molecular Integrated Risk Classes and Prognostic Factors in Endometrial Cancer. (Romantic)

Endometrial Cancer

Italy
Kaohsiung Medical University Chung-Ho Memorial...

Recruiting

AKI Risk Factors Analysis After Intentional Hypotensive Anesthesia

Hypotension Drug-Induced | Acute Kidney Injury (Nontraumatic)

Taiwan
Maastricht University Medical Center

Recruiting

Real-world Evaluation of Diagnostic and Treatment Strategies in Low-Risk Basal Cell Carcinoma (REDT-BCC)

Basal Cell Carcinoma

Netherlands
Nantes University Hospital

Not yet recruiting

Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure (AGORAC)

Organ Grafts

Norway, Spain, France
Changhai Hospital

Not yet recruiting

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical...
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Intrahepatic Cholangiocarcinoma

China
M.D. Anderson Cancer Center
Pfizer

Not yet recruiting

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Multiple Myeloma | Post-transplant MRD-guided Maintenance Therapy | Pre-transplant Purging

United States
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia

High-risk (Secondary) Acute Myeloid Leukemia

China
National Cancer Institute (NCI)

Recruiting

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Neuroblastoma | Ganglioneuroblastoma

United States
National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Washington University School of Medicine
The Leukemia and Lymphoma Society; Rising Tide Foundation; St. Louis Children...

Recruiting

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML (ABCD-NK)

Acute Myeloid Leukemia | Aml | AML, Childhood | Acute Myeloid Leukemia, Pediatric

United States
Wuhan Union Hospital, China

Recruiting

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Extramedullary Multiple Myeloma | Primary Plasma Cell Leukemia

China
Hee Young Ju

Recruiting

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

Lymphoblastic Leukemia in Children

Korea, Republic of
West German Study Group
Merck Sharp & Dohme LLC; Gilead Sciences

Not yet recruiting

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) (ADAPT-TN-III)

Triple Negative Breast Cancer
Assiut University

Not yet recruiting

Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients

Metastatic Breast Cancer

Saudi Arabia
National Cancer Institute (NCI)

Recruiting

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High Risk Resectable Liver Cancer Before Surgery

Resectable Intrahepatic Cholangiocarcinoma

United States
Johns Hopkins All Children's Hospital
Cannonball Kids' Cancer Foundation; Swim Across America Foundation; Benjamin...

Not yet recruiting

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

Lymphocytes

United States
Fred Hutchinson Cancer Center
ImmunoGen, Inc.

Recruiting

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Mixed Phenotype Acute Leukemia

United States
University of California, Irvine

Recruiting

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT)

Allogeneic Hematopoietic Stem Cell Transplantation | Hematologic Malignancies | Allogeneic Stem Cell Transplantation

United States
Margaret Gatti-Mays

Recruiting

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma

United States
St. Jude Children's Research Hospital

Recruiting

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Rhabdomyosarcoma

United States
Fred Hutchinson Cancer Center
National Cord Blood Network

Recruiting

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Hematopoietic and Lymphoid System Neoplasm | Blastic Plasmacytoid Dendritic Cell Neoplasm | Myeloproliferative Neoplasm | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute Leukemia | Chronic...

United States
Sun Yat-sen University
Hainan General Hospital

Recruiting

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Neuroblastoma

China
Eli Lilly and Company

Recruiting

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (CAMPFIRE)

Adolescent | Neoplasms | Child

United States, Spain, United Kingdom, Australia, Italy, Japan, Belgium, France, Germany
The First Hospital of Jilin University
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Diffuse Large B-cell Lymphoma

China
Fudan University

Recruiting

Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer

Stage III Colorectal Cancer | High-risk Stage II Colorectal Cancer | Circulating Tumor DNA Methylation

China
Helwan University

Recruiting

The Incidence of Linezolid-induced Thrombocytopenia (LIT) in Critically Ill Patients, the Risk Factors for LIT

Thrombocytopenia; Drugs

Egypt
The First Affiliated Hospital of Soochow University

Recruiting

VA vs DA for Newly Diagnosed Hig-risk AML

Acute Myeloid Leukemia

China
The First Affiliated Hospital of Soochow University

Recruiting

TFBC Combined With UCBT in the Treatment of High-risk Malignant Hematological Diseases

Hematopoietic Stem Cell Transplantation | Malignant Hematological Diseases

China
Lebanese University
Hospital Saydet Zgharta University Medical Center

Recruiting

LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (LUSZ_AVIST)

COVID-19 | Hospitalized COVID-19 Patients

Lebanon
Zhejiang Cancer Hospital

Recruiting

Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors

Hepatocellular Carcinoma | Oxaliplatin | TACE | Lenvatinib | Tislelizumab | Pharmorubicin

China
Sohag University

Recruiting

Brain-derived Neurotrophic Factor (BDNF) Single Nucleotide Gene Polymorphism and Nerve Growth Factor as Risk Factors That Increase Severity of Allergic Rhinitis

Allergic Rhinitis

Egypt
Fudan University

Recruiting

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Hormone Receptor Positive HER-2 Negative Breast Cancer

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Diffuse Large B Cell Lymphoma

China
Peter MacCallum Cancer Centre, Australia

Recruiting

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma Refractory

Australia
University of California, Davis
National Cancer Institute (NCI); IO Biotech

Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
Sohag University

Not yet recruiting

Evaluation of Risk Factors and Outcome of Thrombosis in Children

Thrombosis in Children

Egypt
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT

Conditioning | Haploidentical Stem Cell Transplantation

China

Search clinical trials for: Molecular risk factors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations